By Scott D. Anthony
Disruptive forces are reconfiguring the biopharmaceutical industry. High profits mask fierce competition, political and reputational challenges, and unrelenting access and affordability pressures. Transformative technologies are enabling new competitors such as Apple, Google, and Nestle to edge into the market.
History teaches us that disruptive change is bad news for even the best-run incumbents. How can executives confront the dilemmas of disruption? The title of our recent book, Dual Transformation, provides our answer.